Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ORKA vs MANE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ORKA Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 8–0 Matrix Metrics)

ORKA Overall Winner 6-Pillar Tally: ORKA 4 – 0 MANE (2 Tie) Matrix Metrics: ORKA 8 – 0 MANE

As of Nov 16, 2026, Oruka Therapeutics, Inc. (ORKA) is the stronger overall head-to-head candidate over MANE (MANE) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ORKA carries a Unified Composite Score of 43.3/100 (HOLD) at $99.83 (N/M Forward P/E, 0.0% operating margin), whereas MANE carries 38.1/100 (SELL) at $128.03 (N/M Forward P/E, N/A operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ORKA vs MANE
ORKA NASDAQ Head-to-Head Winner
Oruka Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.83
-5.23% 1D
Market Cap $7.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.35β · 68% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 24.0 Fund 40.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 55.1 · SMA20: $96.12 · SMA50: $89.82
MANE US Equity
MANE
Institutional Equity
$128.03
-1.26% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.28β · 80% Vol
Unified Composite Score
38.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $137.77 · SMA50: $122.82

6-Pillar Scorecard Institutional Category Breakdown (ORKA 4 – 0 MANE)

Columns: Metric · ORKA · MANE
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ORKA
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A N/A
Market Cap $7.1B N/A
3. Profitability & Quality ORKA
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -18.1% N/A
4. Balance Sheet & Cash Flow ORKA
Cash Generation (TTM) -$124M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $189M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ORKA
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 78.7% (19th %ile) N/A (N/A)
Put/Call OI Skew 0.26x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ORKA (8) vs MANE (0)
Institutional Metric ORKA MANE Criterion Row Edge
Market Capitalization
Scale
$7.1B N/A Larger Scale ORKA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth ORKA
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin ORKA
Net Profit Margin
Profitability
0.0% N/A Higher Margin ORKA
Return on Equity (ROE)
Capital Efficiency
-18.1% N/A Higher ROE ORKA
52-Week Range Position
Momentum
83% ($25–$116) 77% ($32–$157) Stronger Trend ORKA
Beta / 30D Volatility
Risk Regime
1.35β · 68% Vol 1.28β · 80% Vol Lower Realized Risk ORKA
Unified Institutional Score
Composite Signal
43.3 / 100 (HOLD) 38.1 / 100 (SELL) Higher Composite ORKA
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$124M ($189M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ORKA +21.14 pp
ORKA: +38.79% · MANE: +17.65%
3M Horizon MANE +26.73 pp
ORKA: -11.71% · MANE: +15.02%
6M Horizon ORKA +43.58 pp
ORKA: +71.13% · MANE: +27.55%
1Y Horizon MANE +36.62 pp
ORKA: +202.53% · MANE: +239.15%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ORKA vs MANE. Trailing 12-month operating profitability (ORKA 0.0% vs MANE N/A) and valuation multiples (ORKA N/M vs MANE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ORKA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-18.1% · N/M
MANE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ORKA BREAKOUT
141d in phase · OBV ACCUMULATION
Current IV 78.7%
IV Percentile 19th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ORKA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MANE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MANE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ORKA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MANE Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ORKA vs MANE Key Questions & Quantitative Answers

As of Nov 16, 2026, Oruka Therapeutics, Inc. (ORKA) is the stronger overall head-to-head candidate over MANE (MANE) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ORKA carries a Unified Composite Score of 43.3/100 (HOLD) at $99.83 (N/M Forward P/E, 0.0% operating margin), whereas MANE carries 38.1/100 (SELL) at $128.03 (N/M Forward P/E, N/A operating margin). Technically, ORKA sits in a Neutral phase (RSI 55.1, BREAKOUT options structure) and MANE sits in a Neutral phase (RSI 47.0, UNCLASSIFIED options structure).

ORKA leads the Growth & Scale pillar: ORKA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MANE at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ORKA generates N/A in USD-normalized revenue versus N/A for MANE. In operating R&D and SG&A reinvestment, ORKA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MANE.

ORKA and MANE trade at balanced relative valuation multiples. ORKA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MANE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ORKA (-18.1% ROE) versus MANE (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ORKA carries 78.7% implied volatility (19th %ile, Compressed (<25th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.35β · 68% Vol realized risk). By comparison, MANE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.28β · 80% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.